Iovance Biotherapeutics has filed a patent for a method to coordinate the manufacturing of an expanded cell therapy product for cancer treatment. The method involves receiving a cell order request, generating a patient-specific identifier, and expanding the cell therapy product from a solid tumor obtained from the patient. If acceptance parameters are not met at a certain time point, the expansion process can be re-performed. The method also includes coordinating manufacturing, shipping, and patient treatment events, and generating a report of the entire process. GlobalData’s report on Iovance Biotherapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Iovance Biotherapeutics, cytokine activate T-cell based compositions was a key innovation area identified from patents. Iovance Biotherapeutics's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Coordinating manufacturing of expanded t cells for cancer treatment
A recently filed patent (Publication Number: US20230187042A1) describes a method for coordinating the manufacturing of expanded T cells for cancer treatment in patients. The method involves several steps and utilizes computing devices to streamline the process.
The method begins with the manufacturing of a cell therapy product by expanding a population of cells obtained from a tumor in a patient. A patient registration portal is provided via a computing device, allowing hospital personnel to securely register the patient and submit a product order request. This request includes an order identifier associated with a unique patient identifier. The manufacturing facility for the cell therapy product is selected, and information related to the patient and the order request is stored in a central database.
A tumor procurement portal is also provided, enabling hospital personnel to safely extract the biological sample from the patient and associate it with the order identifier. A record of the procedure for extracting the sample, including a chain of custody and inventory of materials used, is created and stored in the central database. The portal also generates a label for the container holding the sample, which includes the order identifier.
The method further includes automation of the manufacturing process, expansion of the cell therapy product using a cell expansion technique, and recording of data related to the manufacturing process and quality control. Labels for containers used in the manufacturing process and for shipping the product to the hospital facility are generated. A schedule of manufacturing and shipping, as well as chain of custody and chain of identity records, are coordinated through computing devices.
The method also involves generating a preliminary schedule of patient treatment events based on the time needed for manufacturing and shipping, as well as the schedule of different patient treatment events. A report is generated, providing an end-to-end process overview from the extraction of the biological sample to the infusion of the manufactured cell therapy product into the patient.
Additional features of the method include enabling third-party access to the schedule of patient treatment events, communication with a customer relationship management (CRM) database for personnel qualification tracking, and coordination of patient support services while maintaining compliance with HIPAA regulations.
Overall, this patent describes a comprehensive method for coordinating the manufacturing of expanded T cells for cancer treatment, utilizing computing devices and central databases to streamline the process and ensure efficient coordination of various steps involved.
To know more about GlobalData’s detailed insights on Iovance Biotherapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
